Sun Pharmaceutical Industries

SUNPHARMA · NSE · INR

₹1,801.00Change from previous close: −0.86%Absolute change: −₹15.60

Close · October 1, 2026

At a glance

Revenue growth
+11.19%
FY to Mar 2026 vs FY to Mar 2025
Net income growth
+5.04%
FY to Mar 2026 vs FY to Mar 2025
Net margin
19.6%
FY to Mar 2025: 20.8%

Financial data

Amounts in millions of INR; per-share values in INR; shares in millions.

Cash flow · Annual
ItemFY to Mar 2026FY to Mar 2025FY to Mar 2024FY to Mar 2023FY to Mar 2022FY to Mar 2021FY to Mar 2020FY to Mar 2019FY to Mar 2018FY to Mar 2017
Operating cash flow124,192140,721121,35049,59389,84561,70465,54821,96539,07270,822
Depreciation and amortization28,69225,07324,90624,77121,09020,29620,08517,22914,77912,410
Capital expenditure-36,094-21,286-22,018-20,856-14,950-11,701-15,420-32,128-19,608-36,929
Investing cash flow-113,441-53,062-6,902-79,437-57,2475,362-25,888-6,813-33,708-42,216
Financing cash flow-25,126-79,058-67,10223,761-51,935-59,805-57,151-27,305-15,393-22,854
Dividends paid-39,339-36,140-28,982-25,189-21,589-15,595-13,792-4,802-7,981-2,399
Share repurchases-38.0-28,999-7740.0—-560-2,125-6,088-6,755-27,308
Debt issued53,22133,61747,15781,59817,63266,029107,705176,975133,68791,976
Debt repaid-35,616-45,266-82,287-31,315-45,286-110,925-138,935-179,347-127,811-81,254
Effect of exchange rates7,7641,230-7401,5711,274-1,2973,6353,2571,473355
Net change in cash-4,9839,83146,6191,155-17,6485,964-13,857-8,442-7,3596,107
Free cash flow88,098119,43599,33228,73874,895—————
Levered free cash flow59,48482,39775,8287,91175,69384,28936,587-39,73734,91929,032